Physician profile
David Mossad
NPI 1821484692
$20,948.78
in general payments reported to CMS, 2019-2025
32 companies · $6,480 in 2025
The $6,480 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $119 · 2021: $434 · 2022: $531 · 2023: $749 · 2024: $12K · 2025: $6,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $3,048 · Travel and Lodging: $1,468 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,620.00 |
| Food and Beverage | $3,048.07 |
| Travel and Lodging | $1,467.62 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $16,783.63 | 2024-2025 | Voquezna |
| Abbvie INC. | $1,443.80 | 2021-2025 | |
| Pfizer INC. | $492.87 | 2019-2025 | |
| Genzyme Corporation | $263.45 | 2023-2025 | |
| Amgen INC. | $254.56 | 2021-2025 | Uplizna |
| Madrigal Pharmaceuticals | $202.87 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $180.74 | 2021-2025 | Tremfya, Stelara |
| Celgene Corporation | $133.83 | 2023-2024 | Zeposia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.80 | 2020-2024 | Cyltezo |
| Amarin Pharma, INC. | $124.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.08 | 2022-2024 | Entyvio |
| Astrazeneca Pharmaceuticals LP | $114.03 | 2019 | |
| Novo Nordisk INC | $112.83 | 2025 | Wegovy |
| Qol Medical, LLC | $101.55 | 2022-2023 | Sucraid |
| Sanofi-Aventis U.S. LLC | $67.06 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $52.93 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $47.29 | 2024 | Clenpiq |
| Ardelyx, INC. | $37.38 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $36.64 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.37 | 2022 | |
| Braintree Laboratories, INC. | $28.99 | 2025 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $24.79 | 2025 | Dupixent |
| Boston Scientific Corporation | $21.71 | 2025 | Watchman Access System |
| Daiichi Sankyo INC. | $19.98 | 2025 | Injectafer |
| Alexion Pharmaceuticals, INC. | $17.98 | 2022 | |
| Gilead Sciences, INC. | $16.52 | 2023 | |
| Vivus LLC | $16.10 | 2021 | |
| Intercept Pharmaceuticals, INC. | $15.62 | 2022 | |
| Aimmune Therapeutics, INC. | $14.90 | 2023 | |
| Evoke Pharma, INC. | $14.19 | 2021 | |
| Redhill Biopharma INC. | $13.72 | 2021 | |
| Fresenius Kabi USA, LLC | $13.58 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mossad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.